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ABSTRACT
AbobotulinumtoxinA (aboBoNT-A, Dysport®) is used in clinical practice as a well-tolerated and effective therapy for muscle 
spasticity. AboBoNT-A has been shown to reduce upper and lower limb spastic paresis in clinical trials, demonstrating 
improvements in muscle tone and limb function. This open-label, multicentre, observational, non-interventional study was 
the first to investigate aboBoNT-A’s efficacy in adult patients with upper limb spasticity (ULS) in routine clinical practice in Po-
land. All enrolled patients received ≥1 aboBoNT-A injection cycles, per routine clinical practice (full analysis set, FAS), and ≥1 
rehabilitation session. Patients attended a baseline visit (V1) and two follow-up visits (V2, V3) for retreatment, depending on 
the investigator’s assessment of individual patient needs, with a mean interval (SD) between injections of 4.4 (1.4) and 4.5 (1.2) 
months. The primary effectiveness endpoint was patient- and physician-based evaluation using the Clinical Global Impression-
-Improvement Scale (CGI-I), a validated 7-point scale (1 = very much improved to 7 = very much worse) relative to baseline. CGI-I 
has not previously been used as a primary endpoint in studies evaluating ULS. Secondary endpoints included muscle tone in 
shoulder, elbow, carpal joint, and finger muscles, measured by the Modified Ashworth Scale (MAS), and muscle strength accor-
ding to the Medical Research Council scale (MRC).
Of 108 enrolled patients (FAS), 92 (85.2%) completed the study and 57 (52.8%) were included in the per protocol (PP) population. 
AboBoNT-A improved patient conditions in 96.4% and 98.6% at V2 and V3 (investigator assessment) and 92.8% and 98.6% (as 
reported by patient) of patients, respectively. Significant reductions in muscle tone from baseline were observed at both visits 
(p < 0.0001–0.0077) across muscle groups. Increased muscle strength by cumulative MRC was observed at V2 (p = 0.0566) and 
V3 (p = 0.0282) versus baseline. Safety was consistent with the known profile of aboBoNT-A. In conclusion, aboBoNT-A treatment 
is beneficial in patients with post-stroke ULS in routine clinical practice, assessed by patients and investigators.
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Introduction
Spasticity is a condition of diverse aetiologies, affecting 
17–38% of patients post-stroke, up to 34% and 40–78% of 
patients who experience traumatic brain injury (TBI) or spinal 
cord injury, respectively, and 17–53% of patients with multiple 
sclerosis [1]. Spasticity prevalence is estimated to be 20% at 
6–18 months post-stroke, although higher figures have been 
reported [2–6]. Spasticity greatly impacts upon the activities 
of daily living and quality of life [7], leading to loss of inde-
pendence, depression, and mood alterations in a substantial 
number of patients [8]. In Poland, approximately 95,000 pa-
tients are hospitalised annually because of acute stroke [6], 
making this condition a significant burden for patients, their 
relatives, and the healthcare system.
Multiple, randomised, controlled clinical trials in patients 
with spasticity have demonstrated that botulinum toxin type 
A (BoNT-A) improves muscle tone, passive function, ease of 
performing passive basic upper limb activities, and physician/
patient global ratings of treatment response [9–15]. Coupled 
with rehabilitation, BoNT-A is recommended for spasticity 
management in clinical practice [14, 16–18].
The clinical efficacy and safety of abobotulinumtoxinA 
(aboBoNT-A, Dysport®, Ipsen Pharma, France) has been con-
firmed in randomised, double-blind clinical trials in different 
neurological conditions, including cervical dystonia [19–21], 
hemifacial paresis [22, 23], blepharospasm [22, 24], paedia-
tric cerebral palsy [25], limb spasticity triggered by multiple 
sclerosis [26], and limb spasticity in adults post-stroke or 
post-TBI [12, 27–31]. 
Moreover, aboBoNT-A has been shown to be an effective 
focal intervention for reducing upper limb spastic paresis 
over single [12, 15] and repeated treatment cycles [31], with 
efficacy lasting up to 20 weeks [12], and exceeding 28 weeks 
when injected early post-stroke [32]. Funding of aboBoNT-A 
for post-stroke ULS treatment in Poland was approved in 2014.
The Clinical Global Impression-Improvement (CGI-I) 
scale is a validated instrument that assesses improvements or 
deteriorations in condition relative to baseline. This scale is 
commonly used in research and is recommended in clinical 
practice for quantifying the progress of patients predominantly 
with psychiatric and movement disorders [33]. The CGI-I has 
been used in published studies for spasticity and toxins [34, 
35]; however, it has not previously been used as a primary end-
point for evaluating upper limb spasticity (ULS) after stroke.
Clinical rationale for the study
The present observational study was the first to evaluate 
the effectiveness of aboBoNT-A in post-stroke ULS based 
on patient and physician CGI-I ratings in real-life clinical 
settings in Poland. The injection regimen was tailored to pa-
tient needs regarding dose and injection frequency, enabling 
individualisation of therapy [12, 34]. These results may provide 
new evidence supporting the effectiveness of aboBoNT-A for 
patients with ULS in routine clinical practice (which includes 
rehabilitation), and will further elucidate whether the CGI-I 
scale is an effective and reliable method to evaluate ULS im-
provements. This study was initiated following the availability 
of funding for aboBoNT-A in Poland. 
Materials and methods
Study design
The primary objective of this open, multicentre, obser-
vational, non-interventional study (NCT02444494) was to 
investigate the clinical effectiveness of aboBoNT-A in adults 
with post-stroke ULS according to patient and physician 
evaluation using the CGI-I scale. 
The secondary objective was to assess muscle tone in mu-
scles of the elbow, wrist, carpal joint, and fingers.
The study was carried out at seven investigational sites in 
Poland between March 2015 and September 2016. The planned 
sequence of events and assessment schedule for each visit are 
presented in Table S1 (see supplementary materials). Visits 
were scheduled based on investigator judgement in accordance 
with routine clinical practice (typically every 3–4 months), 
with at least one rehabilitation cycle.  Study duration was 
approximately nine months for each patient, and 21 months 
overall (including the 12-month recruitment period).
Centres prescribed aboBoNT-A according to the National 
Health Fund (NHF) drug programme. This refers to therapies 
provided by hospitals free of charge for narrowly defined 
groups of patients. 
This study was approved by the Bioethics Commission of 
the District Medical Chamber in Lublin (Komisja Bioetycz-
na przy Okregowej Izbie Lekarskiej w Lublinie); due to the 
non-interventional observational design, the approval of sepa-
rate Commissions was not necessary for each investigational 
site. This study followed the recommendations from the Inter-
national Epidemiological Association Guidelines for the Proper 
Conduct in Epidemiologic Research [36] and the International 
Society for Pharmacoepidemiology Good Pharmacoepide-
miological Practice Guidelines [37], and was conducted in 
accordance with the Declaration of Helsinki. All patients pro-
vided written, informed consent to allow their medical data to 
be collected, analysed and shared with regulatory authorities.  
Inclusion criteria
Patients were eligible to participate if they met the follo-
wing criteria: age ≥ 18 years, history of ischaemic or haemorr-
hagic stroke ≥ 3 months prior to enrollment (documented by 
discharge card from the hospital), post-stroke spasticity of 
confirmed upper extremity (moderate or higher, Modified 
Ashworth Scale [MAS] score ≥ 2) in at least one muscle group, 
or prior inclusion in an NHF Dysport® programme. Classi-
fication of a patient into the programme occurred following 
a designated date of commencement of medical rehabilitation 
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confirmed by the providing rehabilitation services. Drug 
administration took place within three weeks of initiating 
medical rehabilitation. Patients provided written informed 
consent before the initiation of any study-related procedure.
Exclusion criteria
Patients were excluded from the trial if they had severe 
dysphagia and respiratory disorders, were pregnant, had myas-
thenia gravis and myasthenic syndrome (based on neurological 
examination, see supplementary methods; additional tests 
were only carried out in justified cases), had generalised symp-
toms of infection, presented with inflammation at planned 
sites of administration, had fixed contractures in soft tissues 
and joints, or had moderate or severe dementia (Mini Mental 
State Examination [MMSE] score ≤ 18, see supplementary 
methods).
Patient withdrawal
As this was a non-interventional study, there were no spe-
cific predetermined reasons for discontinuing. Patients could 
withdraw consent at any time. In such cases, data was collected 
up to the time of withdrawal, but no additional information 
was collected after this time.
Treatments
Patients who qualified for the post-stroke ULS drug 
programme and attended the treatment centre for routine 
aboBoNT-A treatment received injections, as determined by 
the treating physician. The decision to prescribe aboBoNT-A 
was made prior to and independently from the decision to 
enroll a patient in this study. 
AboBoNT-A is a licensed medication (Dysport®) and was 
therefore presented and packaged according to its marketing 
authorisation. Investigators were free to prescribe any treatment 
dose according to the Polish Summary of Product Characte-
ristics (SmPC) (38) and NHF programme rules. Investigators 
could alter or initiate concomitant medication or physical the-
rapy at any time according to clinical need. To minimise needle 
misplacement during injections, guidance techniques were 
used for the majority of patients. Electrical Muscle Stimulation 
(EMS) was used in 51.1–63.9% of patients and ultrasonography 
(USG) was used in 53.3–68.5% across visits (V1, V2, and V3).
Assessments
The primary effectiveness endpoint was the patient score 
on the CGI-I scale at follow-up visits V2 and V3, assessed 
independently by the investigator and the patient. This scale 
measures change in clinical status from baseline (V1), using 
a 7-point scale, ranging from 1 (very much improved) to 
7 (very much worse), with a score of 4 indicating no change. 
The secondary effectiveness endpoints were global as-
sessment of spasticity, measured on the MAS and measure-
ment of upper limb muscle weakness by Medical Research 
Council (MRC) scale, evaluated at V1, V2, and V3. The MAS 
is a 6-point scale ranging from 0 (no increase in muscle tone) 
to 4 (affected parts rigid in flexion or extension) [39]. MAS 
was evaluated at the joints of each extremity, including sho-
ulders, elbows, wrists, fingers, and thumbs. The MRC scale 
quantifies muscle weakness (range: 0 = absence of movement 
to 5 = muscle contracts normally against full resistance). Ten 
muscle groups were tested, including shoulder adductors, 
shoulder internal rotators, elbow flexors, elbow extensors, 
forearm supinators, forearm pronators, wrist flexors, wrist 
extensors, finger flexors, and thumb adductors. 
CGI-I (patient and investigator), aboBoNT-A administra-
tion (muscle location, dose, and date of injection), neurological 
examination and assessments were recorded in a case report 
form (CRF) designed in accordance with routine practice and 
programme requirements. In addition to data collected du-
ring V1, V2, and V3, CGI-I results from two controlled visits 
between V1 and V2, and V2 and V3 (performed according 
to requirements of the drug programme in post-stroke ULS), 
were collected and reported in the CRF retrospectively using 
patient medical charts. 
Further details of patient characteristics recorded at 
baseline and neurological examinations performed during 
qualification to the drug programme are described in the 
supplementary methods. 
Safety
As this was a non-interventional study, aboBoNT-A was 
administered and managed within routine medical care. 
Investigators reported all serious and non-serious treatment- 
-related adverse events to Ipsen’s Pharmacovigilance Depart-
ment, and recorded such events in the CRF.
Statistical analysis
Analysis populations were defined as enrolled population 
(all patients fully informed about the study who had given 
written informed consent to participate), full analysis set 
(FAS, all enrolled patients having received at least one dose 
of study medication), and per protocol (PP) population (all 
FAS patients with no major protocol violations or deviations).
A sample size of 100 patients was considered appropriate 
to estimate the percentage of patients with CGI-I scale impro-
vements with a required precision of 10% (2-sided 95% CI not 
greater than 9.8 percentage points).
Primary efficacy analysis
CGI-I results were analysed using a 7-point scale and 
assessed using descriptive statistics for categorical variables as 
a percentage for each modality including 95% CI. CGI-I scales 
completed by investigators and patients at V2 and V3 were also 
dichotomised as either ‘improvement’ or ‘no change or wor-
sening’. The proportions of this binary-derived variable were 
analysed using descriptive statistics for qualitative variables 
(exact 95% CI Clopper-Pearson for binomial proportion were 
also presented).
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Secondary efficacy analysis
The CGI-I scale completed by investigators and patients 
between V1 and V2, and between V2 and V3, were analysed 
in the same way as the primary endpoint. Bar charts were 
generated to view the evolution of the distribution of CGI-I 
scale at each time point.
MAS and MRC scores for each joint or muscle group were 
described as ordinal data. For both MAS and MRC, the com-
parison between scores for each joint or muscle group (V2 vs. 
V1, and V3 vs. V1) were tested using the Wilcoxon signed 
rank test. Cumulative MAS (0–20; total score across joints) 
and cumulative MRC (0–50; total score across muscle groups) 
were calculated and described as a quantitative variable if all 
joints or muscle groups were assessed at the corresponding 
visit. Changes from V1 (mean difference and respective 95% 
CI) were analysed using a paired T-test or the Wilcoxon signed 
rank test according to the distribution.
There were no changes to the planned conduct of the study 
and no protocol amendments during the study. MAS and MRC 
scores (for all visits and for each joint or muscle group) and 
respective cumulative data were not displayed for patients for 
whom scores at V1 were missing. If there was a significant 
number of missing values for a patient, a decision was made 
in consultation with the sponsor regarding the handling of 
this data in summaries, prior to a database lock. A sensitivity 
analysis (FAS only) of the primary criterion was performed 
based on the last visit performed for each patient using the 
last observation carried forward method.
Results
Patient disposition
Of 108 patients enrolled, 92 (85.2%) completed the study 
(Tab. 1). All enrolled patients received at least one aboBoNT-A 
injection cycle and were included in the FAS population 
(108 patients; 100%). Of these 108 patients, 57 (52.8%) were 
included in the PP population. Patients were excluded from 
the PP population owing to a missing MMSE score, because 
MMSE score is strongly dependent on language skills [40] 
(23 patients with aphasia; 45.1%), or because of no CGI-I 
assessment completed by either patient or investigator at 
V2 (25 patients; 49.0%) and at V3 (39 patients; 76.5%).
Patient demographics and baseline characteristics
Patient demographics and baseline characteristics are 
shown in Table 2. More male (59.3%) than female patients were 
enrolled, and the mean (SD) age at inclusion was 56.9 (11.9) 
years. The most common type of stroke experienced by patients 
prior to enrollment was cerebral infarction (78.7%), and the 
majority of patients (63.9 %) experienced spasticity pattern III 
(defined in Table 2) [27, 41], with the left (58.3%) being the 
more affected side. Mean time (SD) between stroke diagnosis 
and V1 was 4.5 (5.0) years.
Previous and concomitant comorbidities were recorded in 
24 patients (22.2%) and 73 patients (67.6%) respectively, with 
Table 2. Patient demographics and baseline characteristics
Total (n = 108) 
n
Mean age, years (SD) 56.9 (11.9)
Male, n (%) 64 (59.3)
Mean weight, kg (SD) 77.2 (14.2)
Mean BMI, kg/m2 (SD) 26.7 (4.1)
Mean MMSE scorea (SD) 27.5 (2.5)
Stroke type, n (%)
 Cerebral infarction
 Intracerebral haemorrhage
 Sequelae of CVD
85 (78.7)
23 (21.3)
3 (2.8)
Mean age at stroke, years (SD) 52.3 (12.4)
Mean time between stroke and enrollment, years (SD) 4.5 (5.0)
Mean time between stroke and spasticity, months (SD)b 4.5 (8.5)
Spasticity pattern, n (%)c
 I
 II
 III
 IV
 V
16 (14.8)
3 (2.8)
69 (63.9)
17 (15.7)
3 (2.8)
Laterality affected, n (%)
 Left
 Right
63 (58.3)
45 (41.7)
an = 85; bn = 107; cspasticity pattern definitions from Hefter et al. (2012) [41]
I — internal rotation and adduction of the shoulder, flexion at the elbow, supination in the forearm, 
and flexion at the wrist; 
II — internal rotation and adduction of the shoulder, flexion at the elbow, supination in the fore-
arm, and extension at the wrist; 
III — internal rotation and adduction of the shoulder and flexion at the elbow, coupled with 
a neutral positioning of the forearm and wrist; 
IV — internal rotation and adduction of the shoulder, flexion at the elbow, pronation in the 
forearm, and flexion at the wrist; 
V — internal rotation and retroversion of the shoulder, extension at the elbow, pronation in the 
forearm, and flexion at the wrist.
BMI — body mass index; CVD — cerebrovascular disease; MMSE — mini mental state examination; 
SD — standard deviation
Table 1. Patient disposition
Total (n = 108) 
n (%)
Completers 92 (85.2)
Full analysis set 108 (100)
Per protocol population 57 (52.8)
Withdrawals
     Lack of efficacy
     Consent withdrawn
     Lost to follow-up
     Other
16 (14.8)
2 (1.9)
4 (3.7)
4 (3.7)
6 (5.6)
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Figure 1. Primary efficacy endpoint. A. CGI-I by investigator assessment. B. CGI-I by patient assessment. C. CGI-I overall improvement sum-
mary. For exact values of CGI-I data at V2 and V3, see Table S3 (supplementary materials). CGI-I — Clinical Global Impression-Improvement 
Scale; FAS — full analysis set; PP — per protocol; V — visit
cerebrovascular disease (e.g. previous strokes/silent ischaemic 
events and/or small vascular disease confirmed by magnetic 
resonance imaging) the most prevalent in both cases, expe-
rienced by 17 (15.7%) and 68 (63.0%) patients respectively.
During the study, 92 (85.2%) patients received three 
injection cycles, six (5.6%) received two injection cycles, 
and 10 (9.3%) received only one injection cycle. Mean (SD) 
aboBoNT-A total dose administered at each visit tended to 
decrease, from 853.4 (231.4) U at V1 to 813.8 (264.1) U at V3. 
Further details of injection doses are presented in Table S2 (see 
supplementary materials). Mean (SD) injection intervals 
were 4.4 (1.4) and 4.5 (1.2) months between V1 and V2, and 
V2 and V3, respectively.
Primary efficacy endpoint
CGI-I scale measurements prior to, between, and at 
each follow-up visit are presented in Fig. 1A–C. According 
to both investigator and patient assessments, a high percen-
tage of patients had improved conditions at V2 (96.4% and 
92.8%, respectively) and V3 (98.6% and 98.6%, respectively) 
in the FAS population (Fig.  1A–C, left panels). Similar 
results were observed for the PP population (Fig.  1A–C, 
right panels).
Percentages of improvement by CGI-I scale were similar 
between the two controlled visits (i.e. first and second CGI-I 
between V1 and V2, and first and second CGI-I between 
V2 and V3). All patients in the FAS population evaluated 
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their medical condition as having improved between each 
visit (Fig. 1B), whereas the investigators did not consider the 
medical condition of all patients to be improved (across all 
visits, 95.7–98.8%; Fig. 1A). Despite a substantial number 
of dropouts in the PP population owing to deviations from 
protocol, the results from the FAS and PP populations were 
very similar. Detailed CGI-I score values in the FAS and PP 
populations are presented in Table S3 (see supplementary 
materials).
Secondary efficacy endpoint
MAS
Overall, aboBoNT-A treatment improved muscle tone as 
measured by MAS in the elbows, wrists, fingers, and thumbs in 
the FAS (Fig. 2A–E, left panels) and PP populations (Fig. 2A–E, 
right panels). No significant improvement was detected in 
the shoulders (Fig. 2A). However, shoulder muscles were not 
injected with aboBoNT-A, because shoulders were not inclu-
ded as injection sites in the Polish SmPC at the time of this 
study. Despite this, shoulder measurements were included as 
a separate (Fig. 2A) and sub-measure of the cumulative score, 
as the intention was to assess cumulative improvements in the 
whole upper limb. This reflects patient benefits in everyday life 
and can detect possible effects on shoulder spasticity when 
more distal muscles in upper limbs are injected. MAS scores 
for the FAS and PP populations are detailed in Table S4 (see 
supplementary materials).
There was a decrease in cumulative MAS score at V2 and 
V3 compared to V1 (mean [95% CI]: -1.2 [-1.7; -0.8] and -1.2 
[-1.7; -0.7], respectively; p < 0.0001 for both; FAS), showing 
a statistically significant improvement in medical condition 
(Tab. S5, see supplementary materials), despite the inclusion 
of shoulder muscles.
MRC
The measurements of upper limb muscle weakness by 
MRC for elbow flexors, forearm supinators, forearm prona-
tors, wrist flexors, wrist extensors, finger flexors, and thumb 
adductors for the FAS and PP populations are presented in 
Table S6 (see supplementary materials). In the FAS popula-
tion, significant improvements in MRC score from V1 were 
observed for elbow flexors (p = 0.0094) and finger flexors 
(p = 0.0484) at V2. At V3, significant improvements were recor-
ded for elbow extensors (p = 0.0373), wrist flexors (p = 0.0337), 
and wrist extensors (p = 0.0075). No significant improvements 
were observed in muscles of the forearm, thumb or shoulder. 
In the PP population, change from baseline in MRC score was 
only significant for elbow extensors at V3 (p = 0.0418).
There was a significant increase in cumulative MRC 
score at V3 compared to V1 (mean [95% CI]: 1.0 [0.0; 1.9]; 
p = 0.0282), showing increased muscle strength; however, 
results for V2 were not significant (0.8 [0.0; 1.7]; p = 0.0566; 
FAS). Cumulative MRC score for the FAS and PP populations 
are detailed in Table S7 (see supplementary materials).
Safety
One patient (a 79-year-old male; total dose received 
= 800 U) experienced three adverse reactions (muscle fatigue, 
balance disorder, and drug ineffectiveness). The investigator 
considered the muscle fatigue as possibly being related to 
aboBoNT-A. There were no serious adverse events, deaths, 
or other observations related to safety, in this non-interven-
tional study.
AboBoNT-A dosing, determined by the investigator, 
slightly decreased across study treatments (Tab. S2, see supple-
mentary materials). Dosing was in accordance with Polish 
SmPC and NHF drug programme rules (the maximum indi-
cated dose for upper limb treatment is 1,100 U). Investigators 
injected a high dose according to patient needs in 24 patients 
(1,050 U in two patients and 1,100 U in 22 patients), with no 
subsequent adverse events observed in these patients.
Discussion
This was a non-interventional, observational study desig-
ned to investigate the effectiveness of aboBoNT-A injections 
for ULS in adult patients treated in Polish hospitals. 
We found that treatment with aboBoNT-A within routine 
clinical practice, in parallel with at least one rehabilitation 
session, resulted in not only an overall improvement in patient 
condition as assessed by patients and physicians using the CGI-I 
scale, but also improvements in muscle tone and strength 
assessed using detailed, validated measures (MAS and MRC 
scales) frequently used for spasticity assessment.
The present study was the first to use CGI-I as a primary 
endpoint for ULS assessment, although it has previously been 
used to measure improvements in ULS [34]. CGI-I reflects 
the patients’ overall condition, providing information about 
functional gains, improved limb position and cosmesis, and 
lack of pain [33]. 
In the present study, aboBoNT-A led to improvements 
on the CGI-I scale in almost all patients (92.8–98.6%), as 
reported by both investigator and patient assessment. There 
was no worsening of condition in any patient. These results 
were supported by significant reductions in muscle tone from 
baseline at both visits across different muscle groups. Of 
particular interest, finger muscle improvements may enable 
patients to carry out more precise finger movements. Also, 
muscle strength, as assessed by cumulative MRC, increased 
compared to baseline. 
Upon being included in the study, patients received indi-
vidualised, flexible injection regimens, in which dosing and 
injection frequency were at the investigators’ discretion and 
aligned with routine clinical practice. Mean injection intervals 
(time to retreatment = 4.4 and 4.5 months) were longer than 
the recommended interval of 12 weeks [38], which may re-
duce treatment burden for both patients and physicians [42]. 
This long-lasting efficacy of aboBoNT-A in adult spasticity is 
consistent with previous upper [12, 31] and lower [28] limb 
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Figure 2. Global assessment of spasticity (MAS score) in FAS and PP populations. A. MAS score: shoulder. B. MAS score: elbow. C. MAS 
score: wrist. D. MAS score: finger. E. MAS score: thumb.
Clinician assessment of spasticity and resistance to passive movement. Data presented as percentage of total patients for V1 (FAS: n = 108; 
PP: n = 57), V2 (FAS: n = 98; PP: n = 57), and V3 (FAS: n = 92, FAS; PP: n = 57). Number of patients (n) is provided above percentage bars. 
For exact values in global assessment of spasticity (MAS) data, see Table S4 (supplementary materials). 
FAS — full analysis set; MAS — Modified Ashworth Scale; PP — per protocol; V — visit
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studies. However, retreatment intervals in the present study 
should be considered with caution, as they were not a previo-
usly determined study endpoint and visits represented both 
patients’ needs and a typical interaction between patient and 
physician. The mean subsequent dose of aboBoNT-A was 
notably lower across treatment cycles, as, with time, smaller 
doses of BoNT-A are sufficient to evoke a therapeutic effect, 
and thus dosing was adjusted to individual patient needs.
Improvements in patients’ condition observed in the pre-
sent study occurred despite the relatively long time between 
stroke and aboBoNT-A therapy. Previous studies have shown 
that the time between stroke/TBI and initiation of botulinum 
toxin therapy can impact upon symptom severity. For instance, 
in patients with lower limb spasticity receiving aboBoNT-A, 
the greatest improvements have been observed in patients 
treated 0–2 years post-stroke [28]. Another study showed that 
aboBoNT-A administered early (2–12 weeks) post-stroke for 
ULS significantly delayed time to re-injection (determined 
by pre-defined criteria) to more than 28 weeks in 39.3% of 
patients [43], suggesting that patients can benefit from early 
intervention. Of note, concomitant neurorehabilitation aimed 
at improving upper limb function should be considered as 
a factor that could potentially enhance treatment efficacy.
In this study, separate analyses were performed for the FAS 
and PP populations. The rationale for this was that, firstly, the 
consequences of stroke such as aphasia significantly impact 
upon patient MMSE scores [40, 44], and secondly, that not 
all patients underwent CGI-I assessment by the investigator 
or the patient, leading to fewer patients in the PP population 
compared to the FAS population. Despite the substantial 
dropout in the PP population, CGI-I scale improvements 
according to investigator and patient assessments were similar 
between the FAS and PP populations at each recorded time 
point. The discrepancy in the final inclusion of patients into 
the FAS and PP populations reflects the observational nature 
of this study, and underlines that conditions determined 
a priori in clinical trials might not accurately represent those 
of a real-world setting.
It is important to note that the CGI-I scale is a subjective 
measurement that depends on the patient or investigator by 
whom it is performed, which could be considered a limitation 
of this study. However, it has been proposed that functional 
abilities could be better evaluated based on quality-of-life 
questionnaires rather than objective outcome measures [34]. 
Conclusion
In this non-interventional study, we evaluated the effecti-
veness of up to three aboBoNT-A injection cycles in adults with 
post-stroke ULS in routine clinical practice. This study was the 
first to use the CGI-I scale as a primary endpoint. AboBoNT-A 
led to improvements in CGI-I, by both patient and investigator 
assessment, as well as in muscle tone and muscle strength. No 
new safety information emerged from this study. 
Overall, aboBoNT-A is an effective treatment option for 
patients with ULS, and such improvements can be measured 
reliably using the CGI-I scale.
Clinical implications/future directions 
The results of the present study support the use of 
aboBoNT-A in post-stroke ULS in routine clinical practice. 
The effects of aboBoNT-A were shown to be long-lasting, with 
doses of aboBoNT-A reducing at each subsequent injection 
cycle, consequently easing the burden on both patient and 
physician. The future evaluation of aboBoNT-A in post-stroke 
ULS in routine clinical practice over a longer period may be 
beneficial. The CGI-I scale was shown to be an effective tool 
for measuring improvement in ULS, reliably supporting other 
validated measures. 
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